Physician profile
Benjamin A Barnes
NPI 1942742978
$6,471.48
in general payments reported to CMS, 2019-2025
29 companies · $2,159 in 2025
The $2,159 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $380 · 2022: $761 · 2023: $1,159 · 2024: $2,013 · 2025: $2,159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,310 · Education: $20.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,309.93 |
| Education | $20.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,447.21 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $1,046.47 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $980.44 | 2021-2025 | |
| Pfizer INC. | $464.34 | 2023-2025 | |
| Lilly USA, LLC | $434.26 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $345.34 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $285.47 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $246.29 | 2022-2025 | Jardiance, Synjardy |
| Supernus Pharmaceuticals, INC. | $199.40 | 2024-2025 | Qelbree |
| Janssen Pharmaceuticals, INC | $130.87 | 2021-2022 | |
| Amarin Pharma, INC. | $109.88 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $106.39 | 2021-2022 | |
| Abbott Laboratories | $95.57 | 2023-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $77.04 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Dexcom, INC. | $62.90 | 2021-2023 | Dexcom G6 Transmitter |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $58.97 | 2022-2024 | Repatha, Otezla |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $50.97 | 2025 | Caplyta |
| Esperion Therapeutics, INC. | $44.08 | 2021-2024 | Nexletol |
| Qol Medical, LLC | $41.76 | 2021-2022 | |
| Almatica Pharma LLC | $40.27 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $39.45 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $27.92 | 2024 | Rexulti |
| Merck Sharp & Dohme LLC | $26.94 | 2021 | |
| Idorsia Pharmaceuticals US INC | $25.77 | 2023 | Quviviq |
| Xeris Pharmaceuticals, INC. | $18.83 | 2021 | |
| Nabriva Therapeutics, Plc | $17.90 | 2022 | |
| Biogen, INC. | $16.38 | 2021 | |
| Tris Pharma INC | $16.06 | 2025 | Dyanavel Xr |
| Sanofi-Aventis U.S. LLC | $14.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Barnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.